One agent is JSI-124, a JAK2 inhibitor with NF-κB pathway activating capability based on the structure of cucurbitacin, which has been shown to inhibit proliferation of glioblastoma in vitro and also promote the maturation and T-cell-activating capability of dendritic cells isolated from the spleens of tumor-bearing mice, leading to improved cytotoxicity and growth inhibition with subsequent dendritic cell vaccination [209,213,214,215]. Here, JAK2 is linked to glioblastoma.